ישראל - עברית - Ministry of Health

dexcel ltd, israel - tacrolimus - משחה - tacrolimus 0.1 %w/w - tacrolimus - tacrolimus - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - allopurinol - טבליה - allopurinol 300 mg - allopurinol - allopurinol - management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - allopurinol - טבליה - allopurinol 100 mg - allopurinol - allopurinol - management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride 2 mg - film coated tablets - prolonged release - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 2 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride 8 mg - film coated tablets - prolonged release - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 8 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride 4 mg - film coated tablets - prolonged release - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 4 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.